Cargando…

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment

In a randomized clinical trial in patients initiating glucocorticoid therapy (GC‐I) or on long‐term therapy (GC‐C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. The aim of this study was to evaluate the effects o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geusens, Piet, Bevers, Melissa SAM, van Rietbergen, Bert, Messina, Osvaldo D, Lespessailles, Eric, Oliveri, Beatriz, Chapurlat, Roland, Engelke, Klaus, Chines, Arkadi, Huang, Shuang, Saag, Kenneth G, van den Bergh, Joop P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324223/ https://www.ncbi.nlm.nih.gov/pubmed/35340062 http://dx.doi.org/10.1002/jbmr.4551

Ejemplares similares

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
por: Saag, Kenneth G., et al.
Publicado: (2019)

Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
por: Dempster, David W, et al.
Publicado: (2020)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

The Effect of Bolus Vitamin D(3) Supplementation on Distal Radius Fracture Healing: A Randomized Controlled Trial Using HR‐pQCT
por: Heyer, Frans L, et al.
Publicado: (2021)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
por: Broadwell, Aaron, et al.
Publicado: (2020)

Feasibility of rigid 3D image registration of high-resolution peripheral quantitative computed tomography images of healing distal radius fractures
por: de Jong, Joost J. A., et al.
Publicado: (2017)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Development of a scoring method to visually score cortical interruptions on high-resolution peripheral quantitative computed tomography in rheumatoid arthritis and healthy controls
por: Scharmga, Andrea, et al.
Publicado: (2018)

Distal radius plate of CFR-PEEK has minimal effect compared to titanium plates on bone parameters in high-resolution peripheral quantitative computed tomography: a pilot study
por: de Jong, Joost J. A., et al.
Publicado: (2017)

A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab
por: Chotiyarnwong, Pojchong, et al.
Publicado: (2020)

Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial
por: Body, J.-J., et al.
Publicado: (2020)

Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum
por: Bukata, Susan V., et al.
Publicado: (2021)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case
por: Davidoff, Dahlia F, et al.
Publicado: (2020)

Retraction: Preventive effects of risedronate and calcitriol on cancellous osteopenia in ratstreated with high-dose glucocorticoid
por: IWAMOTO, Jun, et al.
Publicado: (2019)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

Least-detectable and age-related local in vivo bone remodelling assessed by time-lapse HR-pQCT
por: Christen, Patrik, et al.
Publicado: (2018)

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
por: Silver, David S.
Publicado: (2010)

Progress in osteoporosis and fracture prevention: focus on postmenopausal women
por: Saag, Kenneth G, et al.
Publicado: (2009)

Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty
por: Aro, Hannu T, et al.
Publicado: (2019)

Microarchitecture of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva: An HR-pQCT Case Series
por: Botman, Esmée, et al.
Publicado: (2021)

Bone Microarchitecture and Distal Radius Fracture Pattern Complexity
por: Daniels, Anne M., et al.
Publicado: (2019)

A Novel HR‐pQCT Image Registration Approach Reveals Sex‐Specific Changes in Cortical Bone Retraction With Aging
por: van Rietbergen, Bert, et al.
Publicado: (2021)

The Phenotype of Patients with a Recent Fracture: A Literature Survey of the Fracture Liaison Service
por: Vranken, Lisanne, et al.
Publicado: (2017)

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Assessment of Individual Fracture Risk: FRAX and Beyond
por: van den Bergh, Joop P. W., et al.
Publicado: (2010)

The prevalence of vertebral fractures in spondyloarthritis: relation to disease characteristics, bone mineral density, syndesmophytes and history of back pain and trauma
por: Geusens, Piet, et al.
Publicado: (2015)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

Balancing benefits and risks in the era of biologics
por: Adami, Giovanni, et al.
Publicado: (2019)

Optimal Use of Vitamin D When Treating Osteoporosis
por: van den Bergh, Joop P. W., et al.
Publicado: (2010)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

The Effectiveness of Percutaneous Vertebroplasty Is Determined by the Patient-Specific Bone Condition and the Treatment Strategy
por: Widmer Soyka, René P., et al.
Publicado: (2016)

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010)

Comparison of the Effect of Vitamin K(2) and Risedronate on Trabecular Bone in Glucocorticoid-Treated Rats: A Bone Histomorphometry Study
por: Iwamoto, Jun, et al.
Publicado: (2009)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qng6o2l5satbvai1674oq1mkdg